Conclusion
Based upon our experience, LVAD implantation in sickle-cell trait is safe and offers a remarkable improvement in patient outcomes. In spite of the limited numbers of patients enrolled in this case-series, the findings suggest that LVAD implantation can be successfully performed in patients with SCD trait by applying meticulous pre-operative, intra-operative, anesthetic, and post-operative management protocols. However, the literature on the specific evaluation and management of these patients remains limited and further studies are still needed to provide more evidences on this practice.